Skip to main content
PMC home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2008 Feb 1;5(1):33–39. doi: 10.1007/s11904-008-0006-4

The potential of RNA interference-based therapies for viral infections

Diana D Huang 1,✉
PMCID: PMC7088822  PMID: 18417033

Abstract

RNA interference (RNAi) is a natural mechanism in cells that suppresses or silences the expression of aberrant or foreign genes. This activity is being developed as a potential antiviral therapeutic strategy. Studies in vitro, and some in vivo, appear to show the feasibility of using RNAi to treat virus infection. Therapeutic use of RNAi seems to be promising when directed against viruses that cause localized acute infections in accessible target cells. Therapeutic strategies using RNAi against viruses that cause chronic infections, such as HIV, hepatitis B virus, or hepatitis C virus, are more difficult to design, but studies have begun to address identifiable problems. Two clinical trials using RNAi have recently been initiated—one phase II trial against respiratory syncytial virus and a phase I trial against HIV. It will be of much interest to see whether nucleic acid therapies can offer another route to treating viral infection.

Keywords: Respiratory Syncytial Virus, West Nile Virus Infection, Japanese Encephalitis Virus, RNAi Therapy, Nucleic Acid Therapy

References and Recommended Reading

  • 1.Rossi JJ: Interference and inhibition: RNAi mechanisms and therapeutic prospects. Presented at the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention. Sydney, Australia; July 22–25, 2007.
  • 2.Li M., Li H., Rossi J.J. RNAi in combination with a ribozyme and TAR decoy for treatment of HIV infection in hematopoietic cell gene therapy. Ann N Y Acad Sci. 2006;1082:172–179. doi: 10.1196/annals.1348.006. [DOI] [PubMed] [Google Scholar]
  • 3.Robbins M.A., Li M., Leung I., et al. Stable expression of shRNAs in human CD34+ progenitor cells can avoid induction of interferon responses to siRNAs in vitro. Nat Biotechnol. 2006;24:566–571. doi: 10.1038/nbt1206. [DOI] [PubMed] [Google Scholar]
  • 4.Michienzi A., Castanotto D., Lee N., et al. RNA-mediated inhibition of HIV in a gene therapy setting. Ann N Y Acad Sci. 2003;1002:63–71. doi: 10.1196/annals.1281.008. [DOI] [PubMed] [Google Scholar]
  • 5.Scherer L., Rossi J.J., Weinberg M.S. Progress and prospects: RNA-based therapies for treatment of HIV infection. Gene Ther. 2007;14:1057–1064. doi: 10.1038/sj.gt.3302977. [DOI] [PubMed] [Google Scholar]
  • 6.Yeung M.L., Bennasser Y., Le S.Y., Jeang K.T. siRNA, miRNA and HIV: promises and challenges. Cell Res. 2005;15:935–946. doi: 10.1038/sj.cr.7290371. [DOI] [PubMed] [Google Scholar]
  • 7.Wilson J.F. Gene therapy yields to RNA interference. Ann Intern Med. 2005;143:161–164. doi: 10.7326/0003-4819-143-2-200507190-00033. [DOI] [PubMed] [Google Scholar]
  • 8.Amado R.G., Mitsuyasu R.T., Rosenblatt J.D., et al. Antihuman immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. Hum Gene Ther. 2004;15:251–262. doi: 10.1089/104303404322886101. [DOI] [PubMed] [Google Scholar]
  • 9.Levine B.L., Humeau L.M., Boyer J., et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A. 2006;103:17372–17377. doi: 10.1073/pnas.0608138103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Tijsterman M., Ketting R.F., Plasterk R.H. The genetics of RNA silencing. Annu Rev Genet. 2002;36:489–519. doi: 10.1146/annurev.genet.36.043002.091619. [DOI] [PubMed] [Google Scholar]
  • 11.Leonard J.N., Schaffer D.V. Antiviral RNAi therapy: emerging approaches for hitting a moving target. Gene Ther. 2006;13:532–540. doi: 10.1038/sj.gt.3302645. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Check E. Pioneering HIV treatment would use interference and gene therapy. Nature. 2005;437:601. doi: 10.1038/437601b. [DOI] [PubMed] [Google Scholar]
  • 13.Grimm D., Kay M.A. Therapeutic short hairpin RNA expression in the liver: viral targets and vectors. Gene Ther. 2006;13:563–575. doi: 10.1038/sj.gt.3302727. [DOI] [PubMed] [Google Scholar]
  • 14.Dykxhoorn D.M., Lieberman J. Knocking down disease with siRNAs. Cell. 2006;126:231–235. doi: 10.1016/j.cell.2006.07.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Dykxhoorn D.M., Lieberman J. Silencing viral infection. PLoS Med. 2006;3:e242. doi: 10.1371/journal.pmed.0030242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.de Fougerolles A., Vornlocher H.P., Maraganore J., Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov. 2007;6:443–453. doi: 10.1038/nrd2310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Zamore P.D., Aronin N. siRNAs knock down hepatitis. Nat Med. 2003;9:266–267. doi: 10.1038/nm0303-266. [DOI] [PubMed] [Google Scholar]
  • 18.Boden D., Pusch O., Lee F., et al. Human immunodeficiency virus type 1 escape from RNA interference. J Virol. 2003;77:11531–11535. doi: 10.1128/JVI.77.21.11531-11535.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Das A.T., Brummelkamp T.R., Westerhout E.M., et al. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol. 2004;78:2601–2605. doi: 10.1128/JVI.78.5.2601-2605.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Westerhout E.M., Ooms M., Vink M., et al. HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res. 2005;33:796–804. doi: 10.1093/nar/gki220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Wilson J.A., Richardson C.D. Hepatitis C virus replicons escape RNA interference induced by a short interfering RNA directed against the NS5b coding region. J Virol. 2005;79:7050–7058. doi: 10.1128/JVI.79.11.7050-7058.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Palliser D., Chowdhury D., Wang Q.Y., et al. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature. 2006;439:89–94. doi: 10.1038/nature04263. [DOI] [PubMed] [Google Scholar]
  • 23.Bitko V., Musiyenko A., Shulyayeva O., Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med. 2005;11:50–55. doi: 10.1038/nm1164. [DOI] [PubMed] [Google Scholar]
  • 24.Ge Q., Filip L., Bai A., et al. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci U S A. 2004;101:8676–8681. doi: 10.1073/pnas.0402486101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Tompkins S.M., Lo C.Y., Tumpey T.M., Epstein S.L. Protection against lethal influenza virus challenge by RNA interference in vivo. Proc Natl Acad Sci U S A. 2004;101:8682–8686. doi: 10.1073/pnas.0402630101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Li B.J., Tang Q., Cheng D., et al. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat Med. 2005;11:944–951. doi: 10.1038/nm1280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Kumar P., Lee S.K., Shankar P., Manjunath N. A single siRNA suppresses fatal encephalitis induced by two different flaviviruses. PLoS Med. 2006;3:e96. doi: 10.1371/journal.pmed.0030096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Morrissey D.V., Blanchard K., Shaw L., et al. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology. 2005;41:1349–1356. doi: 10.1002/hep.20702. [DOI] [PubMed] [Google Scholar]
  • 29.Morrissey D.V., Lockridge J.A., Shaw L., et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol. 2005;23:1002–1007. doi: 10.1038/nbt1122. [DOI] [PubMed] [Google Scholar]
  • 30.Chen C.C., Ko T.M., Ma H.I., et al. Long-term inhibition of hepatitis B virus in transgenic mice by double-stranded adeno-associated virus 8-delivered short hairpin RNA. Gene Ther. 2007;14:11–19. doi: 10.1038/sj.gt.3302846. [DOI] [PubMed] [Google Scholar]
  • 31.McCaffrey A.P., Nakai H., Pandey K., et al. Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol. 2003;21:639–644. doi: 10.1038/nbt824. [DOI] [PubMed] [Google Scholar]
  • 32.Ying R.S., Zhu C., Fan X.G., et al. Hepatitis B virus is inhibited by RNA interference in cell culture and in mice. Antiviral Res. 2007;73:24–30. doi: 10.1016/j.antiviral.2006.05.022. [DOI] [PubMed] [Google Scholar]
  • 33.Klein C., Bock C.T., Wedemeyer H., et al. Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. Gastroenterology. 2003;125:9–18. doi: 10.1016/S0016-5085(03)00720-0. [DOI] [PubMed] [Google Scholar]
  • 34.Merl S., Michaelis C., Jaschke B., et al. Targeting 2A protease by RNA interference attenuates coxsackieviral cytopathogenicity and promotes survival in highly susceptible mice. Circulation. 2005;111:1583–1592. doi: 10.1161/01.CIR.0000160360.02040.AB. [DOI] [PubMed] [Google Scholar]
  • 35.Xiong D., Lee G.H., Badorff C., et al. Dystrophin deficiency markedly increases enterovirus-induced cardiomyopathy: a genetic predisposition to viral heart disease. Nat Med. 2002;8:872–877. doi: 10.1038/nm737. [DOI] [PubMed] [Google Scholar]
  • 36.Fechner H., Pinkert S., Wang X., et al. Coxsackievirus B3 and adenovirus infections of cardiac cells are efficiently inhibited by vector-mediated RNA interference targeting their common receptor. Gene Ther. 2007;14:960–971. doi: 10.1038/sj.gt.3302948. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Jopling C.L., Yi M., Lancaster A.M., et al. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science. 2005;309:1577–1581. doi: 10.1126/science.1113329. [DOI] [PubMed] [Google Scholar]
  • 38.Song E., Lee S.K., Wang J., et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med. 2003;9:347–351. doi: 10.1038/nm828. [DOI] [PubMed] [Google Scholar]
  • 39.Niu X.Y., Peng Z.L., Duan W.Q., et al. Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo. Int J Gynecol Cancer. 2006;16:743–751. doi: 10.1111/j.1525-1438.2006.00384.x. [DOI] [PubMed] [Google Scholar]
  • 40.Yokota T., Iijima S., Kubodera T., et al. Efficient regulation of viral replication by siRNA in a non-human primate surrogate model for hepatitis C. Biochem Biophys Res Commun. 2007;361:294–300. doi: 10.1016/j.bbrc.2007.06.182. [DOI] [PubMed] [Google Scholar]
  • 41.Novina C.D., Murray M.F., Dykxhoorn D.M., et al. siRNA-directed inhibition of HIV-1 infection. Nat Med. 2002;8:681–686. doi: 10.1038/nm725. [DOI] [PubMed] [Google Scholar]
  • 42.Qin X.F., An D.S., Chen I.S., Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci U S A. 2003;100:183–188. doi: 10.1073/pnas.232688199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Anderson J., Akkina R. HIV-1 resistance conferred by siRNA cosuppression of CXCR4 and CCR5 coreceptors by a bispecific lentiviral vector. AIDS Res Ther. 2005;2:1. doi: 10.1186/1742-6405-2-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Bennasser Y., Le S.Y., Benkirane M., Jeang K.T. Evidence that HIV-1 encodes an siRNA and a suppressor of RNA silencing. Immunity. 2005;22:607–619. doi: 10.1016/j.immuni.2005.03.010. [DOI] [PubMed] [Google Scholar]
  • 45.Cave E., Weinberg M.S., Cilliers T., et al. Silencing of HIV-1 subtype C primary isolates by expressed small hairpin RNAs targeted to gag. AIDS Res Hum Retroviruses. 2006;22:401–410. doi: 10.1089/aid.2006.22.401. [DOI] [PubMed] [Google Scholar]
  • 46.Lee S.K., Dykxhoorn D.M., Kumar P., et al. Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV. Blood. 2005;106:818–826. doi: 10.1182/blood-2004-10-3959. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Sabariegos R., Gimenez-Barcons M., Tapia N., et al. Sequence homology required by human immunodeficiency virus type 1 to escape from short interfering RNAs. J Virol. 2006;80:571–577. doi: 10.1128/JVI.80.2.571-577.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Current HIV/AIDS Reports are provided here courtesy of Nature Publishing Group

RESOURCES